+91 757 4878 021

Heritage

Founding History and CMD Message

The Rich Heritage of Baroque Pharma

" Established in 1994 by Chairman and Managing Director Mr. J.D. Patel, Baroque is committed to delivering high-quality, cost-effective medicines globally. With operations in India and various international markets through key partnerships, we are dedicated to innovation and excellence.
A leading-edge R&D centre enhances our capabilities in oral solid and liquid NDDS technologies. Our world-class manufacturing facilities are approved by numerous regulatory authorities across Europe, Africa, South Asia, CIS, Latin America, Southeast Asia, Central Asia, and the Middle East.
We view excellence as an ongoing pursuit, continuously striving to develop facilities and systems that align with our goal of providing world-class medicines.
With a humble beginning decades ago, our saga still continues to grow under the vision of strong leader whose passion and spirit of perseverance has percolated and imbibed into the entire Team Baroque. "

A Vision Beyond Limits: Our Healthcare Journey

"A degree in my hand, a dream in my eyes to create a company which adds value to healthcare and a desire in my heart to create opportunities for those who are my own was all I had when I embarked on this journey years ago. The times were changing. Benefits and incentives were in place to spur the much necessary growth of the Pharma industry that promised a sea of opportunities for a start up. But the limitation of financial, human and technological resources made the task onerous, especially doing this at the place where we did it,. But having pledged to this responsibility I continued with my efforts over the years. Slowly a team was falling in place, people who believed in my dream and were ready to sweat for it. We kept learning, we kept evolving; we kept emerging out of all difficulties. Many a milestones have been achieved since then. But the dream is bigger than what’s been attained. The company is still young and still growing in terms of products, therapeutics segments, technological platforms, and the markets where we operate. The purpose still remains the same but the out reach will be bigger in the times to come. "